Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China OKs Heterologous Booster Shots Amid Heated COVID Vaccine Race

Major Commercial Opportunity Opens Up

Executive Summary

CanSino and Zhifei have received the regulatory green light for their respective COVID-19 booster shots in China and an estimated $1.3bn vaccine market is now up for grabs. Domestic contenders are set to elbow each other in the sector with a range of viral vector, recombinant protein and mRNA-based jabs.

You may also be interested in...



China's 'Two Sessions': Vaccines, Drugs Seen Key To Easing Restrictions Amid New Spike

The latest policies from Beijing show that the Chinese government is readying its own new vaccines and drugs for COVID-19 in a bid to gradually ease some of the strictest pandemic restrictions globally, but progress is mixed and domestic reported infections are surging to their highest level since March 2020.

New Modalities Help Chinese Biotechs Win Investors’ Attention

Five Chinese bioventures have raised more than $70m from venture capital and private equity funds since late May.

Drought Ending? Shanghai’s STAR Market Considers Two IPO Applicants

With the first half of 2022 ending, two Chinese developers of innovative drugs - antibody specialist Chongqing Genrix Biopharmaceutical and Suzhou Teligene, which focuses on small molecules, are looking to go public on Shanghai’s STAR Market, ending a recent drought of biopharma listings.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145948

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel